| Autor: |
Faure, Nacia, Labrie, Fernand, Lemay, André, Bélanger, Alain, Gourdeau, Yves, Laroche, Bruno, Robert, Gilles |
| Zdroj: |
Fertility and Sterility; March 1982, Vol. 37 Issue: 3 p416-424, 9p |
| Abstrakt: |
The effect of chronic treatment with the luteinizing hormone-releasing hormone (LH-RH) agonist Buserelin (Hoechst AG, Frankfurt/Main, West Germany) ([d-Ser(TBU)6,des-Gly-NH210]LH-RH ethylamide) administered by nasal spray (200 or 500 μg, twice daily) or subcutaneously (50 μg daily) for periods of 1 to 8 months was studied on serum sex steroids and LH levels in 18 patients with cancer of the prostate. Basal serum testosterone concentration decreases to 71.1±18.3 (NS) and 28.6±9.3%, (P<0.01) of control in patients receiving the 200-μg and 500-μg dose by nasal spray, respectively. In patients treated subcutaneously, a more rapid inhibition of serum testosterone levels to 19.6±6.4% of control (P<0.01) is observed. The finding of decreased levels of 17-OH-progesterone, testosterone, and dihydrotestosterone in the presence of unchanged pregnenolone concentration indicates that the decrease in androgen biosynthesis induced by Buserelin treatment is due to a blockage at the level of 17-hydroxylase and 17,20-desmolase activities. The present data indicate that chronic administration of Buserelin could be a safe and effective means of reducing serum androgens in patients with cancer of the prostate. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
